References: Kawasaki disease

Ha KS, Jang G, Lee J, Lee K, Hong Y, Son C, et al. Incomplete clinical manifestation as a risk factor for coronary artery abnormalities in Kawasaki disease: a meta-analysis. Eur J Pediatr 2013;172(3):343-9. https://www.ncbi.nlm.nih.gov/pubmed/23229186
Ig Governance. Kawasaki disease (mucocutaneous lymph node syndrome) version 3.1. Criteria for clinical use of immunoglobulin in Australia. Canberra: National Blood Authority. 2021; Accessed Nov 2022. https://www.criteria.blood.gov.au/MedicalCondition/View/2666
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017;135(17):e927-e99. https://www.ncbi.nlm.nih.gov/pubmed/28356445
The Royal Children's Hospital (RCH) Melbourne. Kawasaki disease. Clinical Practice Guidelines. Melbourne: RCH. Updated Jan 2021. Accessed Nov 2022. https://www.rch.org.au/clinicalguide/guideline_index/Kawasaki_disease/
Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2017;1(1):CD011188. https://www.ncbi.nlm.nih.gov/pubmed/28129459